AgendaSpeakersAttendeesOverview WSGR website

Conference Agenda

Thursday June 25, 2015
Sharon Heights Golf and Country Club
2900 Sand Hill Road
Menlo Park, CA

6:00 – 9:00 p.m.

Medical Device Dinner Interview with Steve Blank
Join David Cassak in conversation with Steve Blank on the Lean LaunchPad approach to building Medtech startups. Steve is an entrepreneur with eight tech startups under his belt. He retired to become a writer and educator, and in the process launched the “Lean Startup” movement. Today Steve lectures on entrepreneurship at Berkeley, Stanford, Columbia, NYU and UCSF, and in 2009 was awarded the Stanford University Undergraduate Teaching Award in Management Science.

Friday June 26, 2015

Palace Hotel
2 New Montgomery Street
San Francisco, CA

7:00 – 8:00 a.m.

Conference Registration and Continental Breakfast

8:00 – 8:10 a.m.

Welcome, Casey McGlynn, Wilson Sonsini Goodrich & Rosati

8:10 – 9:10 a.m.

Venture Capital Today
Getting a new medical device company funded is harder today. An ever-shrinking pool of investors interested in early-stage life science investing, larger capital requirements due to prolonged regulatory and reimbursement timelines, and the need for true sales traction to garner the attention of potential corporate acquirers have all become the hallmarks of the current financing environment. How are investors adapting their financing strategies and business models to accommodate these realities and position themselves for long-term success? Join a panel of Medtech investors to explore their approaches to investing in these changing times.

9:10 – 9:30 a.m.


9:30 – 10:30 a.m.

Breakout Session 1

Innovative Deal Structures
Several Investors, Corporate Development Executives, and CEOs will review recent corporate partnering transactions. Learn about how young venture backed companies worked with large Medtech consolidators to create win-win structures. Listen to a discussion on key business terms in early and late stage deals. Join a discussion about the differing structures and key terms involved in these transactions.

Collaborations Between Japan and Silicon Valley
There is growing interest from Japan to invest in and collaborate with US Medtech companies, venture funds and incubators, many of which are located in Silicon Valley. For the first time in many years the major Japanese trading companies are focusing on reenergizing their Medtech businesses. This represents a major opportunity for Silicon Valley startups to seek investments from and partnerships with Japanese businesses. Join this panel to learn about the ways in which Japan and Silicon Valley startups are collaborating to finance and develop advanced medical technologies.

Important M&A Deals
An investment banker, two successful CEOs, and a corporate development executive from a Medtech consolidator will join this panel to explore structured M&A transactions--deals involving earnouts and milestones. Recent deal terms will be explored as well as a retrospective look at how successful these transactions are in delivering value to shareholders and acquirers. Join us for a lively discussion about these transactions from the view of both the buyer and seller.

10:30 – 10:50 a.m.


10:50 – 11:50 a.m.

Breakout Session 2

Corporate Investors and Buyers
Meet corporate investors from two large Medtech consolidators. Learn about the interests of each company in corporate partnering with emerging Medtech companies. Hear about the typical arrangements corporate acquirers like to structure and the therapeutic areas of interest to them today. This panel will also include information on how these arrangements can come undone and ways to make sure the deal ends up as a win-win transaction that will benefit management, investors and the acquirers.

A Case Study in Payer/Provider/Medtech Collaboration
Highmark Blue Cross Blue Shield and its major provider system, the Allegheny Health Network, have created a unique innovation program that is designed to accelerate the adoption of exciting medical devices. The VITAL Innovation program is targeted to FDA approved but unreimbursed devices that are expected to drive quality up at the right cost. The program is attractive to young companies in that they can test their devices, define and measure outcome, clarify the concept of value, explore paths to reimbursement and develop a path to mutual success. This session will share how the program operates from the perspectives of the payor, provider and the companies and explore how this alignment of interests can have relevance for the Medtech industry as a whole. VITAL is a new model that aligns and unites the interests of previously misaligned groups that all seek to improve the health of patients.

Successful De Novo 510K Strategies
Learn the secrets of the De Novo 510k Pathway. Interestingly this alternative to the lengthy premarket approval process has never quite caught on among device makers. In fact, it remains one of the least traveled routes to market for new devices. Meet the executives from emerging Medtech companies as they explain their experience with this pathway and today’s slimmed down process to approval. Is the De Novo Pathway right for your device? Ask the experts on this panel.

11:50 a.m. – 12:10 p.m.


12:10 – 1:10 p.m.

Breakout Session 3

Commercialization Strategies
Historically building a large sales force to sell important breakthrough Medtech products has been the recipe for a successful acquisition. But has the world changed? What new kind of sales structures will be required in the future? Will sales forces get smaller as the buy decision is increasingly made by the finance department instead of the doctor? Join a panel of CEOs who have launched new products, build sales organizations and created very successful businesses in the past as they look at the evolving commercialization strategies required for product adoption.

International Funding Strategies – China
Join a panel of experienced Chinese investors and advisors who can help you fund your company or help you to establish and fund a business unit of your company in China. Learn how these transactions are structured and the reasons that draw Chinese investor to the US and US entrepreneurs to China.

Lean LaunchPad
In today’s tough funding climate, innovation in science and technology is not enough. The Lean LaunchPad approach to building Medtech startups focuses on getting founders “out of the building” to solicit direct feedback from customers and critical stakeholders, providing an early testing of core hypotheses and allowing immediate refinements in critical business model assumptions. This “Lean” approach shifts startup thinking from writing business plans and immediate execution to the early testing of critical hypotheses about business, allowing adjustments or pivots on little or no capital. Join Steve Bank and Allan May and several CEOs as they discuss the Lean LaunchPad Concept and the things that entrepreneurs need to have in place before they start to look for money.

1:10 – 2:40 p.m.

Lunch Interview: JNJ and Google Collaborate on Advanced Surgical Robotics
Perhaps you saw the recent announcement that Johnson & Johnson and Google were collaborating on an Advanced Surgical Robot to give surgeons greater control, access and accuracy during the surgical procedure while benefitting patients by minimizing trauma and scarring, enabling accelerated post-surgical healing. Join this lunch panel as David Cassak discusses the project with Ken Drazon M.D., Head of Johnson & Johnson Innovation in Menlo Park.

2:40 – 3:40 p.m.

Breakout Session 4

Medtech IPO’s Are Back
Several Medtech companies have completed IPOs this year and underwriters are actively pitching IPOs to mature Medtech companies. From this vantage point we reach mid-year 2015 with an expanding IPO market for high quality Medtech companies. With this as a background, our panel will explore current investor appetite for Medtech IPOs, the status of the emerging window for public offerings and the likely minimum requirements to be considered an attractive Medtech IPO candidate.

Patient Monitoring – Cutting Through the Hype
There is so much hype surrounding remote patient monitoring (RPM) and related buzz terms--like wearables, mobile apps, big data, the Internet of Things (IoT), and mHealth--that sometimes it is difficult to separate hyperbole from reality. What opportunities does RPM really afford medical device makers? What should they do to take advantage? How do wearables fit into the equation? Should the Medtech industry fear or embrace the involvement of tech titans like Google and Apple? Join a panel of experts from tech and Medtech as they explore the role of remote patient monitoring in our future.

The USPTO Comes to the Silicon Valley
Obtaining patents is crucial for medical technology companies. Join a panel including the new head of the USPTO Silicon Valley satellite office and a USPTO Supervisory Patent Examiner experienced in medical technologies, as well as experienced patent counsel and a seasoned entrepreneur as they discuss working for and with the PTO. The panel will explore successful strategies for prosecuting and expediting patent applications in the US, as well as utilizing the resources of the new Silicon Valley satellite PTO office.

3:40 – 4:00 p.m.


4:00– 5:00 p.m.

Medtech Innovator
A group of early stage companies will present their pitch to a group of active medical device investors. These companies will vie for the title of Medtech Innovator. The investors will evaluate each of the presentations and give feedback to each of the companies that present, and the audience will select the winner using electronic polling. The winner will receive recognition at an awards ceremony during the conference. They will also get a presenting slot at the upcoming ADVAMED Annual Meeting. For those interested in applying, please submit an application at

5:00 – 6:30 p.m.

Venture Capital Uncorked
Join Wilson Sonsini Goodrich & Rosati for wine tasting after the conference. We will be sampling wines from various wineries, with venture capitalists serving as your sommeliers for the event. This is your chance to try some great wine and learn a little bit more about what each of our local venture firms is looking for in its next deal. It's a great pairing—wine with a venture capital twist.